77 related articles for article (PubMed ID: 26166370)
1. Bu-Shen-Ning-Xin decoction suppresses osteoclastogenesis via increasing dehydroepiandrosterone to prevent postmenopausal osteoporosis.
Gui Y; Qiu X; Xu Y; Li D; Wang L
Biosci Trends; 2015 Jun; 9(3):169-81. PubMed ID: 26166370
[TBL] [Abstract][Full Text] [Related]
2. Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α.
Wang L; Qiu XM; Gui YY; Xu YP; Gober HJ; Li DJ
Drug Des Devel Ther; 2015; 9():3755-66. PubMed ID: 26229438
[TBL] [Abstract][Full Text] [Related]
3. Bu-Shen-Ning-Xin Decoction ameliorated the osteoporotic phenotype of ovariectomized mice without affecting the serum estrogen concentration or uterus.
Wang L; Qiu XM; Gui YY; Xu YP; Gober HJ; Li DJ
Drug Des Devel Ther; 2015; 9():5019-31. PubMed ID: 26357466
[TBL] [Abstract][Full Text] [Related]
4. Bu‑Shen‑Ning‑Xin decoction suppresses osteoclastogenesis by modulating RANKL/OPG imbalance in the CD4+ T lymphocytes of ovariectomized mice.
Zhang JL; Qiu XM; Zhang N; Tang W; Gober HJ; Li DJ; Wang L
Int J Mol Med; 2018 Jul; 42(1):299-308. PubMed ID: 29717766
[TBL] [Abstract][Full Text] [Related]
5. Bu-Shen-Tong-Luo decoction prevents bone loss via inhibition of bone resorption and enhancement of angiogenesis in ovariectomy-induced osteoporosis of rats.
Yuan H; Xiao L; Min W; Yuan W; Lu S; Huang G
J Ethnopharmacol; 2018 Jun; 220():228-238. PubMed ID: 29317302
[TBL] [Abstract][Full Text] [Related]
6. Bu-Shen-Ning-Xin decoction inhibits macrophage activation to ameliorate premature ovarian insufficiency-related osteoimmune disorder via FSH/FSHR pathway.
Sun H; Qi Q; Pan X; Zhou J; Wang J; Li L; Li D; Wang L
Drug Discov Ther; 2024 Jun; 18(2):106-116. PubMed ID: 38631868
[TBL] [Abstract][Full Text] [Related]
7. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
8. Differential regulation of dehydroepiandrosterone and estrogen on bone and uterus in ovariectomized mice.
Wang L; Wang YD; Wang WJ; Li DJ
Osteoporos Int; 2009 Jan; 20(1):79-92. PubMed ID: 18690485
[TBL] [Abstract][Full Text] [Related]
9. Effects of Bu-Shen-Ning-Xin Decoction on immune cells of the spleen and bone marrow in ovariectomized mice.
Qiu X; Gui Y; Zhang N; Xu Y; Li D; Wang L
Biosci Trends; 2016 Nov; 10(5):400-409. PubMed ID: 27476527
[TBL] [Abstract][Full Text] [Related]
10. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
11. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
12. Dehydroepiandrosterone inhibited the bone resorption through the upregulation of OPG/RANKL.
Wang YD; Wang L; Li DJ; Wang WJ
Cell Mol Immunol; 2006 Feb; 3(1):41-5. PubMed ID: 16549048
[TBL] [Abstract][Full Text] [Related]
13. Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis.
Kameda Y; Takahata M; Mikuni S; Shimizu T; Hamano H; Angata T; Hatakeyama S; Kinjo M; Iwasaki N
Bone; 2015 Feb; 71():217-26. PubMed ID: 25460183
[TBL] [Abstract][Full Text] [Related]
14. DHEA prevents bone loss by suppressing the expansion of CD4(+) T cells and TNFa production in the OVX-mouse model for postmenopausal osteoporosis.
Zhang N; Gui Y; Qiu X; Tang W; Li L; Gober HJ; Li D; Wang L
Biosci Trends; 2016 Sep; 10(4):277-87. PubMed ID: 27464762
[TBL] [Abstract][Full Text] [Related]
15. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
[TBL] [Abstract][Full Text] [Related]
16. Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor.
Wang L; Wang YD; Wang WJ; Zhu Y; Li DJ
J Mol Endocrinol; 2007 Apr; 38(4):467-79. PubMed ID: 17446236
[TBL] [Abstract][Full Text] [Related]
17. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
18. Tenuigenin inhibits RANKL-induced osteoclastogenesis by down-regulating NF-κB activation and suppresses bone loss in vivo.
Yang S; Li X; Cheng L; Wu H; Zhang C; Li K
Biochem Biophys Res Commun; 2015 Oct; 466(4):615-21. PubMed ID: 26392312
[TBL] [Abstract][Full Text] [Related]
19. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
20. Jolkinolide B inhibits RANKL-induced osteoclastogenesis by suppressing the activation NF-κB and MAPK signaling pathways.
Ma X; Liu Y; Zhang Y; Yu X; Wang W; Zhao D
Biochem Biophys Res Commun; 2014 Mar; 445(2):282-8. PubMed ID: 24491533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
